Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Provided By GlobeNewswire
Last update: Feb 10, 2025
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC
Amezalpat builds momentum with both Fast Track and Orphan Drug Designations
Read more at globenewswire.com6.78
-0.12 (-1.74%)
Find more stocks in the Stock Screener
TPST Latest News and Analysis
12 days ago - ChartmillLet's uncover which stocks are experiencing notable gaps during today's session.Let's have a look at the gap up and gap down stocks in today's session.
12 days ago - ChartmillGet insights into the top gainers and losers of Monday's pre-market session.The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
